How is elvitegravir (EVG) administered in antiretroviral therapy for HIV infection in adolescents and young adults?

Updated: Mar 16, 2020
  • Author: David J Cennimo, MD, FAAP, FACP, AAHIVS; Chief Editor: Michelle R Salvaggio, MD, FACP  more...
  • Print
Answer

Answer

 

Elvitegravir (EVG)

  • Vitekta: 85 mg or 150 mg used in combination with an HIV protease inhibitor (ie, atazanavir, lopinavir, darunavir, fosamprenavir, or tipranavir) and coadministered with ritonavir plus other antiretroviral drug(s) as indicated for the treatment of HIV-1 infection in antiretroviral treatment–experienced adults; limited data (off-label) available for adolescents aged 12-17 y
  • Stribild: Elvitegravir is a component of the FDA-approved “quad” pill, elvitegravir/cobicistat/emtricitabine/tenofovir TD (Stribild) approved for adults and adolescents aged 12 y or older who weigh at least 35 kg. Combination formulation including EVG 150 mg/Cobi 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg; take once daily with food
  • Genvoya: Identical to elvitegravir with the exception that it contains 10 mg of tenofovir alafenamide (AF). It is approved for adults and adolescents aged 12 y or older who weigh at least 35 kg.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!